文献速递流行病学与生物统计临床试验与 GCP

卒中病因分型的可靠性及其对试验样本量的影响:系统综述、荟萃分析与统计建模

Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling.
PubMed 文献 · Trials · 2019-02-08

该系统综述从4655篇文献中纳入14篇,量化三种卒中病因分型系统的观察者间可靠性,并基于虚国际卒中试验档案数据建模错分对假设性心源性卒中抗凝试验样本量的影响。结果显示错分率为5%和20%时,检测生存差异所需样本量分别从198例增至237例和352例,卒中复发结局所需样本量分别从502例增至605例和973例。

要点

  • 卒中病因分型系统存在观察者间变异,可靠性从一般到很好不等。
  • 错分可膨胀试验所需样本量,5%错分即增加约20%样本量。
  • 心源性卒中试验中非心源性病因污染会降低检验效能。

核心结论

  • 卒中病因分型系统存在观察者间变异,由此产生的错分可能限制试验检验效能。

研究设计与样本

  • 系统综述从4655篇文献中纳入14篇描述三种卒中病因分型系统的文章,量化观察者间可靠性。
  • 基于系统综述的可靠性汇总估计设定错分率,从虚国际卒中试验档案中随机抽样心源性与非心源性卒中急性期试验数据。
  • 采用自举法在5000次置换中建模不同错分率对检测组间治疗效应所需样本量的影响,结局为90天生存和卒中复发。

主要发现

  • 分型系统的观察者间可靠性从「一般」到「很好」不等,建模采用5%和20%的错分率。
  • 假设性心源性卒中抗凝 vs 抗血小板试验,80%把握度和α=0.05检测生存差异,每组需198例。
  • 5%错分污染使所需样本量膨胀至237例,20%错分膨胀至352例。
  • 卒中复发结局每组基础样本量为502例,5%污染增至605例,20%污染增至973例。

临床怎么用

  • 设计卒中病因相关临床试验时需考虑分型错分对样本量的影响,适当增加样本量以维持检验效能。

局限性

  • 错分率基于系统综述的可靠性汇总估计,可能受原始研究异质性影响。
  • 样本量建模基于假设性试验和虚国际卒中试验档案数据,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Inter-observer variability in stroke aetiological classification may have an effect on trial power and estimation of treatment effect. We modelled the effect of misclassification on required sample size in a hypothetical cardioembolic (CE) stroke trial. METHODS: We performed a systematic review to quantify the reliability (inter-observer variability) of various stroke aetiological classification systems. We then modelled the effect of this misclassification in a hypothetical trial of anticoagulant in CE stroke contaminated by patients with non-cardioembolic (non-CE) stroke aetiology. Rates of misclassification were based on the summary reliability estimates from our systematic review. We randomly sampled data from previous acute trials in CE and non-CE participants, using the Virtual International Stroke Trials Archive. We used bootstrapping to model the effect of varying misclassification rates on sample size required to detect a between-group treatment effect across 5000 permutations. We described outcomes in terms of survival and stroke recurrence censored at 90 days. RESULTS: From 4655 titles, we found 14 articles describing three stroke classification systems. The inter-observer reliability of the classification systems varied from 'fair' to 'very good' and suggested misclassification rates of 5% and 20% for our modelling. The hypothetical trial, with 80% power and alpha 0.05, was able to show a difference in survival between anticoagulant and antiplatelet in CE with a sample size of 198 in both trial arms. Contamination of both arms with 5% misclassified participants inflated the required sample size to 237 and with 20% misclassification inflated the required sample size to 352, for equivalent trial power. For an outcome of stroke recurrence using the same data, base-case estimated sample size for 80% power and alpha 0.05 was n = 502 in each arm, increasing to 605 at 5% contamination and 973 at 20% contamination. CONCLUSIONS: Stroke aetiological classification systems suffer from inter-observer variability, and the resulting misclassification may limit trial power. TRIAL REGISTRATION: Protocol available at reviewregistry540 .

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Abdul-Rahim AH, Dickie DA, Selvarajah JR, et al. Stroke aetiological classification reliability and effect on trial sample size: systematic review, meta-analysis and statistical modelling. Trials. 2019. PMID: 30736833. doi:10.1186/s13063-019-3222-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。